Cargando…

Discovery of SARS-CoV-2 3CL(Pro) Peptidomimetic Inhibitors through the Catalytic Dyad Histidine-Specific Protein–Ligand Interactions

As the etiological agent for the coronavirus disease 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) challenges the ongoing efforts of vaccine development and drug design. Due to the accumulating cases of breakthrough infections, there are urgent needs for broad-spectrum antiviral...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Yaxin, Xu, Binghong, Ma, Sen, Wang, Hao, Shang, Luqing, Zhu, Cheng, Ye, Sheng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8878928/ https://www.ncbi.nlm.nih.gov/pubmed/35216507 http://dx.doi.org/10.3390/ijms23042392

Ejemplares similares

4-Iminooxazolidin-2-One as a Bioisostere of Cyanohydrin Suppresses EV71 Proliferation by Targeting 3C(pro)
por: Xu, Binghong, et al.
Publicado: (2021)

Conformationally Constrained Histidines in the Design of Peptidomimetics: Strategies for the χ-Space Control
por: Stefanucci, Azzurra, et al.
Publicado: (2011)

Design, synthesis and biological evaluation of peptidomimetic benzothiazolyl ketones as 3CL(pro) inhibitors against SARS-CoV-2
por: Yang, Hanxi, et al.
Publicado: (2023)

Human defensin-inspired discovery of peptidomimetic antibiotics
por: Luo, Gan, et al.
Publicado: (2022)

The structure-based design of peptidomimetic inhibitors against SARS-CoV-2 3C like protease as Potent anti-viral drug candidate
por: Wang, Hao, et al.
Publicado: (2022)

Peptidomimetics and Their Applications for Opioid Peptide Drug Discovery
por: Lee, Yeon Sun
Publicado: (2022)

Design, synthesis and biological evaluation of covalent peptidomimetic 3CL protease inhibitors containing nitrile moiety
por: Zhu, Mengwei, et al.
Publicado: (2023)

Development of peptidomimetic ligands of Pro-Leu-Gly-NH(2) as allosteric modulators of the dopamine D(2) receptor
por: Bhagwanth, Swapna, et al.
Publicado: (2013)

Triazole-Modified Peptidomimetics: An Opportunity for Drug Discovery and Development
por: Staśkiewicz, Agnieszka, et al.
Publicado: (2021)

Editorial: Peptidomimetics: Synthetic Tools for Drug Discovery and Development
por: Del Gatto, Annarita, et al.
Publicado: (2021)

Fragment-Based Library Generation for the Discovery of a Peptidomimetic p53-Mdm4 Inhibitor
por: Boltjes, André, et al.
Publicado: (2014)

The Discovery of Conformationally Constrained Bicyclic Peptidomimetics as Potent Hepatitis C NS5A Inhibitors
por: Kazmierski, Wieslaw M., et al.
Publicado: (2021)

SARS-CoV-2 M(pro): A Potential Target for Peptidomimetics and Small-Molecule Inhibitors
por: Citarella, Andrea, et al.
Publicado: (2021)

Editorial of Special Column “Novel Peptides and Peptidomimetics in Drug Discovery”
por: Cai, Jianfeng, et al.
Publicado: (2021)

Protease inhibitors and their peptidomimetic derivatives as potential drugs
por: Fear, Georgie, et al.
Publicado: (2007)

Discovery of Potent Peptidomimetic Antagonists for Heterochromatin Protein 1 Family Proteins
por: Lamb, Kelsey N., et al.
Publicado: (2021)

An Overview of Severe Acute Respiratory Syndrome–Coronavirus (SARS-CoV) 3CL Protease Inhibitors: Peptidomimetics and Small Molecule Chemotherapy
por: Pillaiyar, Thanigaimalai, et al.
Publicado: (2016)

Membrane Sensor Histidine Kinases: Insights from Structural, Ligand and Inhibitor Studies of Full-Length Proteins and Signalling Domains for Antibiotic Discovery
por: Ma, Pikyee, et al.
Publicado: (2021)

Peptidomimetics II
por: Lubell, William D
Publicado: (2016)

Contribution of the catalytic dyad of SARS-CoV-2 main protease to binding covalent and noncovalent inhibitors
por: Kovalevsky, Andrey, et al.
Publicado: (2023)

Discovery of chebulagic acid and punicalagin as novel allosteric inhibitors of SARS-CoV-2 3CL(pro)
por: Du, Ruikun, et al.
Publicado: (2021)

Polyacylated anthocyanins constructively network with catalytic dyad residues of 3CL(pro) of 2019-nCoV than monomeric anthocyanins: A structural-relationship activity study with 10 anthocyanins using in-silico approaches
por: Khalifa, Ibrahim, et al.
Publicado: (2020)

Inhibition of the severe acute respiratory syndrome 3CL protease by peptidomimetic α,β-unsaturated esters
por: Shie, Jiun-Jie, et al.
Publicado: (2005)

Discovery of 9,10-dihydrophenanthrene derivatives as SARS-CoV-2 3CL(pro) inhibitors for treating COVID-19
por: Zhang, Jian-Wei, et al.
Publicado: (2022)

Functional Role of Histidine in the Conserved His-x-Asp Motif in the Catalytic Core of Protein Kinases
por: Zhang, Lun, et al.
Publicado: (2015)

Peptidomimetics in cancer targeting
por: Gomari, Mohammad Mahmoudi, et al.
Publicado: (2022)

Peptides and Peptidomimetics as Inhibitors of Enzymes Involved in Fibrillar Collagen Degradation
por: Ledwoń, Patrycja, et al.
Publicado: (2021)

Rational Design of a Peptidomimetic Inhibitor of Gelsolin Amyloid Aggregation
por: Bollati, Michela, et al.
Publicado: (2022)

Computational Insights into Substrate and Site Specificities, Catalytic Mechanism, and Protonation States of the Catalytic Asp Dyad of β-Secretase
por: Barman, Arghya, et al.
Publicado: (2014)

Editor Profiles: Guest Editors of Special Column “Novel Peptides and Peptidomimetics in Drug Discovery”()
Publicado: (2021)

Hydrolysis of Methionine- and Histidine-Containing Peptides Promoted by Dinuclear Platinum(II) Complexes with Benzodiazines as Bridging Ligands: Influence of Ligand Structure on the Catalytic Ability of Platinum(II) Complexes
por: Rajković, Snežana, et al.
Publicado: (2018)

Peptidomimetic inhibitors of N-myristoyltransferase from human malaria and leishmaniasis parasites
por: Olaleye, Tayo O., et al.
Publicado: (2014)

Development of Peptidomimetics Targeting IAPs
por: Sharma, Sushil K., et al.
Publicado: (2006)

Using the ribosome to synthesize peptidomimetics
por: Freidinger, Roger M
Publicado: (2009)

Short Cationic Peptidomimetic Antimicrobials
por: Kuppusamy, Rajesh, et al.
Publicado: (2019)

Promising Antibiofilm Activity of Peptidomimetics
por: Gomes Von Borowski, Rafael, et al.
Publicado: (2018)

Peptidomimetics Therapeutics for Retinal Disease
por: Parsons, Dylan E., et al.
Publicado: (2021)

Cell-free Biosynthesis of Peptidomimetics
por: Lee, Kanghun, et al.
Publicado: (2023)

Discovery of novel non-peptidic and non-covalent small-molecule 3CL(pro) inhibitors as potential candidate for COVID-19 treatment
por: Jiang, Zhidong, et al.
Publicado: (2023)

Rapid de novo discovery of peptidomimetic affinity reagents for human angiotensin converting enzyme 2
por: Zhang, Genwei, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_rf7c3hn4qjcnljgt10mbgepovs